Ann: Investor Presentation and Investor Meetings, page-66

The company didnt have a near fda approved product in that time.

Sofdra has proven itself in overseas markets already and continues to show strong growth in Japan.

The US is the gold standard. We are in a completely different era here with this company then we were prior. Getting companies through trial phases is expensive. Without SB BOT would have gone broke like many others have, IHL is actually a fine example.

BOT has done that with Sofdra and has diversified products heading into phase 3 trials elsewhere.

You are still here because you know this. Otherwise find something else as compelling as this to invest in. You have another chance with BOT here. It will run again, you are waiting for it intently i know.

Most investors know leading into phase 2/3 trials and during fda approval lead time is where money is made. No different here again mate.

When you buy back in mate, do us a favour and tell us. Otherwise you will end up like old mate @Pilbars too embarrassed to return!